<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052428</url>
  </required_header>
  <id_info>
    <org_study_id>F040601008</org_study_id>
    <nct_id>NCT01052428</nct_id>
  </id_info>
  <brief_title>Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)</brief_title>
  <acronym>P1A1</acronym>
  <official_title>Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular
      matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure
      in the volume overload of mitral regurgitation (MR). Patients without coronary artery disease
      and moderate MR, as assessed by color/flow Doppler echocardiography, will be randomized to
      ß1-RB vs. placebo to address the following aims:

      *Aim 1: Establish whether ß1-RB attenuates adverse LV remodeling compared to placebo in
      patients with non-surgical, chronic MR. Using 3-dimensional magnetic resonance imaging (MRI)
      and tissue tagging, LV function and geometry will be assessed at baseline and every 6 months
      for up to 2 years.

      Aim 2: Determine whether indices of inflammation correlate with degree of LV remodeling and
      whether ß1-RB decrease indices of inflammation and collagen turnover. At the time of MRI,
      blood samples for collagen breakdown products, matrix metalloproteinase (MMP) activity, and
      markers of excess production of reactive inflammatory species (RIS) will be obtained and
      related to changes in LV remodeling defined by serial 3-dimensional MRI and tissue tagging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Western society, the most common causes of chronic mitral regurgitation (MR) are ischemic
      heart disease and myxomatous degeneration of the valve, resulting in prolapse, ruptured
      chordae or partial flail leaflet. Current indications for surgery are only for patients with
      severe MR and either notable symptoms or overt Left Ventricular (LV) dysfunction (ejection
      fraction &lt; 60%, end-systolic diameter &gt; 40 mm). Therefore, despite the availability of
      surgery, most patients with MR of moderate severity are not immediate candidates for surgery,
      warranting analysis of potential beneficial effects of medical treatment. Chronic therapy
      with vasodilators reduces LV wall stress and thereby delays the need for valve replacement in
      aortic regurgitation; however, no such data are currently available in patients with chronic
      MR using standard vasodilators or agents that block the renin angiotensin system (RAS).

      In a clinically-relevant dog model of MR, the investigators have shown increased LV ACE and
      chymase expression, increased LV angiotensin II but, as opposed to pressure overload, there
      was an absence of fibrosis with net extracellular matrix (ECM) degradation and activation of
      matrix metalloproteinases (MMPs). However, blockade of the RAS does not improve (and may
      actually exacerbate) LV remodeling in MR. Interestingly, the investigators and others have
      shown that ß1-receptor blockade (ß1-RB) is more effective than RAS blockade in attenuating
      progressive LV remodeling and ECM degradation in MR. Moreover, increased sympathetic drive
      and inflammation has been identified in patients with chronic MR. ß1-RB reduced plasma
      markers of inflammation in patients with heart failure and resulted in substantial reverse LV
      remodeling in patients with heart failure. Taken together, activation of the adrenergic
      nervous system early in the course of volume overload contributes to increased production of
      reactive inflammatory species (RIS) and that one mechanism underlying the salutary effects of
      ß1-blockade may relate to attenuation of myocardial formation of RIS with subsequent
      beneficial effects on MMP activation and ECM and LV remodeling and function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular End Diastolic Volume Indexed to Body Surface Area</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular End-Diastolic Radius to Wall Thickness</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular End Systolic Volume Indexed to Body Surface Area</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Longitudinal Strain</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Early Filling Rate: Rate of Change Over Time</measure>
    <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
    <description>Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Toprol XL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beta 1 receptor blockade; generic name metoprolol succinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol succinate (Toprol XL)</intervention_name>
    <description>Toprol XL 100 mg once a day for 2 years</description>
    <arm_group_label>Toprol XL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 100 mg once a day for 2 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients who have Moderate MR documented by color flow doppler:

          1. LV ejection fraction &gt; 55%; LV end-systolic dimension &lt; 4.0 cm.

          2. Quantifiable by Doppler-Echo equal or more than moderate in severity.

          3. Organic disease of the mitral valve demonstrated by echocardiography (not normal valve
             as in functional or ischemic MR).

          4. Isolated MR (no valve disease other than mild tricuspid or pulmonic regurgitation by
             Doppler-Echocardiography that is often associated with mitral valve prolapse).

          5. Asymptomatic (or mildly symptomatic but not considered as candidates for immediate
             surgery by their attending physician).

        Exclusion Criteria:

          1. Significant obstructive coronary artery disease and/or myocardial ischemia on graded
             exercise test with myocardial perfusion.

          2. Previous myocardial infarction or percutaneous coronary intervention.

          3. Hypertrophic cardiomyopathy, congenital or pericardial disease.

          4. Aortic valve disease (&gt; trace aortic regurgitation or mean gradient &gt; 10 mmHg).

          5. Mitral stenosis (mean gradient &gt;5 mmHg, valve area &lt; 1.5 cm2).

          6. Intolerance or contraindication to Beta1-AR blockade.

          7. Renal failure with creatinine &gt; 2.5 mg/dl.

          8. Hypertension requiring medical treatment or renal artery stenosis.

          9. Severe comorbidity: liver disease, malignancy, collagen vascular, steroid requirement.

         10. Pregnancy (negative pregnancy test and effective contraceptive methods are required
             prior to enrollment of females of childbearing potential).

         11. Uncontrolled (rate &gt; 120/min) or recent (&lt;4 weeks) atrial fibrillation.

         12. Routine, regular use of anti-inflammatory medications.

        Exclusion Criteria Related to MRI

          1. Severe claustrophobia.

          2. Presence of a pacemaker or non-removable hearing aid.

          3. Presence of metal clips in the body.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis . J. Dell'Italia, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>1. Dell'Italia LJ. Mitral Regurgitation. In Hurst The Heart. Eds. O'Rourke, Sclhant, Alexader, Fuster. 11th Edition, Chapter 57 pp 1169-1695, 2004.</citation>
  </reference>
  <reference>
    <citation>Olson LJ, Subramanian R, Ackermann DM, Orszulak TA, Edwards WD. Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years. Mayo Clin Proc. 1987 Jan;62(1):22-34.</citation>
    <PMID>3796056</PMID>
  </reference>
  <reference>
    <citation>Otto CM. Timing of surgery in mitral regurgitation. Heart. 2003 Jan;89(1):100-5. Review.</citation>
    <PMID>12482807</PMID>
  </reference>
  <reference>
    <citation>Wisenbaugh T, Essop R, Rothlisberger C, Sareli P. Effects of a single oral dose of captopril on left ventricular performance in severe mitral regurgitation. Am J Cardiol. 1992 Feb 1;69(4):348-53.</citation>
    <PMID>1734647</PMID>
  </reference>
  <reference>
    <citation>Röthlisberger C, Sareli P, Wisenbaugh T. Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation. Am J Cardiol. 1994 May 15;73(13):978-81.</citation>
    <PMID>8184862</PMID>
  </reference>
  <reference>
    <citation>Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis. 1994 Mar;3(2):197-204.</citation>
    <PMID>8012639</PMID>
  </reference>
  <reference>
    <citation>Marcotte F, Honos GN, Walling AD, Beauvais D, Blais MJ, Daoust C, Lisbona A, McCans JL. Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Can J Cardiol. 1997 May;13(5):479-85.</citation>
    <PMID>9179087</PMID>
  </reference>
  <reference>
    <citation>Høst U, Kelbaek H, Hildebrandt P, Skagen K, Aldershvile J. Effect of ramipril on mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 1997 Sep 1;80(5):655-8.</citation>
    <PMID>9295005</PMID>
  </reference>
  <reference>
    <citation>Tischler MD, Rowan M, LeWinter MM. Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 1998 Jul 15;82(2):242-5.</citation>
    <PMID>9678300</PMID>
  </reference>
  <reference>
    <citation>Dujardin KS, Enriquez-Sarano M, Bailey KR, Seward JB, Tajik AJ. Effect of losartan on degree of mitral regurgitation quantified by echocardiography. Am J Cardiol. 2001 Mar 1;87(5):570-6.</citation>
    <PMID>11230841</PMID>
  </reference>
  <reference>
    <citation>Gaasch WH, Aurigemma GP. Inhibition of the renin-angiotensin system and the left ventricular adaptation to mitral regurgitation. J Am Coll Cardiol. 2002 Apr 17;39(8):1380-3.</citation>
    <PMID>11955859</PMID>
  </reference>
  <reference>
    <citation>Stewart JA Jr, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi PA, Janicki JS, Dell'Italia LJ. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol. 2003 Mar;35(3):311-9.</citation>
    <PMID>12676546</PMID>
  </reference>
  <reference>
    <citation>Perry GJ, Wei CC, Hankes GH, Dillon SR, Rynders P, Mukherjee R, Spinale FG, Dell'Italia LJ. Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol. 2002 Apr 17;39(8):1374-9.</citation>
    <PMID>11955858</PMID>
  </reference>
  <reference>
    <citation>Dell'italia LJ, Balcells E, Meng QC, Su X, Schultz D, Bishop SP, Machida N, Straeter-Knowlen IM, Hankes GH, Dillon R, Cartee RE, Oparil S. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol. 1997 Aug;273(2 Pt 2):H961-70.</citation>
    <PMID>9277516</PMID>
  </reference>
  <reference>
    <citation>Nemoto S, Hamawaki M, De Freitas G, Carabello BA. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol. 2002 Jul 3;40(1):149-54.</citation>
    <PMID>12103269</PMID>
  </reference>
  <reference>
    <citation>Tallaj J, Wei CC, Hankes GH, Holland M, Rynders P, Dillon AR, Ardell JL, Armour JA, Lucchesi PA, Dell'Italia LJ. Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation. Circulation. 2003 Jul 15;108(2):225-30. Epub 2003 Jul 7.</citation>
    <PMID>12847066</PMID>
  </reference>
  <reference>
    <citation>Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G 4th, Carabello BA. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 1994 Jun;93(6):2639-48.</citation>
    <PMID>7911128</PMID>
  </reference>
  <reference>
    <citation>Mehta RH, Supiano MA, Oral H, Grossman PM, Montgomery DS, Smith MJ, Starling MR. Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. Am Heart J. 2003 Jun;145(6):1078-85.</citation>
    <PMID>12796766</PMID>
  </reference>
  <reference>
    <citation>Mehta RH, Supiano MA, Oral H, Grossman PM, Petrusha JA, Montgomery DG, Briesmiester KA, Smith MJ, Starling MR. Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. Am J Cardiol. 2000 Dec 1;86(11):1193-7.</citation>
    <PMID>11090790</PMID>
  </reference>
  <reference>
    <citation>Oral H, Sivasubramanian N, Dyke DB, Mehta RH, Grossman PM, Briesmiester K, Fay WP, Pagani FD, Bolling SF, Mann DL, Starling MR. Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation. 2003 Feb 18;107(6):831-7.</citation>
    <PMID>12591752</PMID>
  </reference>
  <reference>
    <citation>Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, Eng C. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999 May 25;99(20):2645-51.</citation>
    <PMID>10338457</PMID>
  </reference>
  <reference>
    <citation>Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992 Oct;263(1):92-8.</citation>
    <PMID>1357162</PMID>
  </reference>
  <reference>
    <citation>Flesch M, Maack C, Cremers B, Bäumer AT, Südkamp M, Böhm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation. 1999 Jul 27;100(4):346-53.</citation>
    <PMID>10421593</PMID>
  </reference>
  <reference>
    <citation>Chin BS, Langford NJ, Nuttall SL, Gibbs CR, Blann AD, Lip GY. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail. 2003 Mar;5(2):171-4.</citation>
    <PMID>12644008</PMID>
  </reference>
  <reference>
    <citation>Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000 Jun;6(2 Suppl 1):8-14. Review.</citation>
    <PMID>10908093</PMID>
  </reference>
  <reference>
    <citation>Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002 May 28;105(21):2512-7.</citation>
    <PMID>12034658</PMID>
  </reference>
  <reference>
    <citation>Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, Martínez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindán JP, Díez J. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000 Apr 11;101(14):1729-35.</citation>
    <PMID>10758057</PMID>
  </reference>
  <reference>
    <citation>López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, Díez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001 Jul 17;104(3):286-91.</citation>
    <PMID>11457746</PMID>
  </reference>
  <reference>
    <citation>Cracowski JL, Tremel F, Marpeau C, Baguet JP, Stanke-Labesque F, Mallion JM, Bessard G. Increased formation of F(2)-isoprostanes in patients with severe heart failure. Heart. 2000 Oct;84(4):439-40.</citation>
    <PMID>10995421</PMID>
  </reference>
  <reference>
    <citation>Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998 Apr 28;97(16):1536-9.</citation>
    <PMID>9593557</PMID>
  </reference>
  <reference>
    <citation>Nonaka-Sarukawa M, Yamamoto K, Aoki H, Takano H, Katsuki T, Ikeda U, Shimada K. Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart. 2003 Aug;89(8):871-4.</citation>
    <PMID>12860861</PMID>
  </reference>
  <reference>
    <citation>Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest. 2001 Dec;120(6):2035-46. Review.</citation>
    <PMID>11742938</PMID>
  </reference>
  <reference>
    <citation>Rouleau JL, Pitt B, Dhalla NS, Dhalla KS, Swedberg K, Hansen MS, Stanton E, Lapointe N, Packer M; Canadian Prospective RandOmized FlosequInan Longevity Evaluation Investigators. Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. Am Heart J. 2003 May;145(5):926-32.</citation>
    <PMID>12766756</PMID>
  </reference>
  <reference>
    <citation>López Farré A, Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension. 2001 Dec 1;38(6):1400-5. Review.</citation>
    <PMID>11751725</PMID>
  </reference>
  <reference>
    <citation>Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002 May-Jun;8(3):132-40. Review.</citation>
    <PMID>12045381</PMID>
  </reference>
  <reference>
    <citation>Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma GP, Devereux RB. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002 Jul 9;106(2):227-32.</citation>
    <PMID>12105163</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>July 29, 2011</results_first_submitted>
  <results_first_submitted_qc>March 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2012</results_first_posted>
  <last_update_submitted>November 16, 2012</last_update_submitted>
  <last_update_submitted_qc>November 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Dr. Louis J. Dell'Italia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic MR</keyword>
  <keyword>Volume Overload</keyword>
  <keyword>Beta-1 receptor blocker</keyword>
  <keyword>LV remodelling, LV dimensions</keyword>
  <keyword>LV systolic function</keyword>
  <keyword>LV diastolic dysfunction</keyword>
  <keyword>Cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Toprol-XL</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Toprol-XL</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="9.3"/>
                    <measurement group_id="B2" value="55.9" spread="9.2"/>
                    <measurement group_id="B3" value="54.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular End Diastolic Volume Indexed to Body Surface Area</title>
        <description>Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Volume Indexed to Body Surface Area</title>
          <description>Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium.</description>
          <population>intent to treat</population>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.66" spread="16.48"/>
                    <measurement group_id="O2" value="95.74" spread="19.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.93">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.84" spread="16.39"/>
                    <measurement group_id="O2" value="95.24" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.56">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.99" spread="16.63"/>
                    <measurement group_id="O2" value="95.71" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.73" spread="14.18"/>
                    <measurement group_id="O2" value="98.16" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.16" spread="21.49"/>
                    <measurement group_id="O2" value="97.6" spread="19.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.75" spread="15.24"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.31" spread="20.91"/>
                    <measurement group_id="O2" value="95.16" spread="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4568</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume</title>
        <description>Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume</title>
          <description>Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium.</description>
          <population>intent to treat</population>
          <units>g/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.13"/>
                    <measurement group_id="O2" value="0.61" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.11"/>
                    <measurement group_id="O2" value="0.6" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67">n=1</measurement>
                    <measurement group_id="O2" value="0.53">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.12"/>
                    <measurement group_id="O2" value="0.60" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.18"/>
                    <measurement group_id="O2" value="0.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.11"/>
                    <measurement group_id="O2" value="0.59" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.13"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.12"/>
                    <measurement group_id="O2" value="0.62" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1967</p_value>
            <p_value_desc>not adjusted for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular End-Diastolic Radius to Wall Thickness</title>
        <description>Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-Diastolic Radius to Wall Thickness</title>
          <description>Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium.</description>
          <population>intent to treat</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="0.92"/>
                    <measurement group_id="O2" value="4.69" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="0.62"/>
                    <measurement group_id="O2" value="4.85" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15">n=1</measurement>
                    <measurement group_id="O2" value="5.74">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" spread="0.64"/>
                    <measurement group_id="O2" value="4.79" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="1.69"/>
                    <measurement group_id="O2" value="5.02" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="0.69"/>
                    <measurement group_id="O2" value="4.77" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.91"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" spread="0.78"/>
                    <measurement group_id="O2" value="4.59" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>not adjusted for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular End Systolic Volume Indexed to Body Surface Area</title>
        <description>Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Volume Indexed to Body Surface Area</title>
          <description>Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium.</description>
          <population>intent to treat</population>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.01" spread="6.86"/>
                    <measurement group_id="O2" value="35.98" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.83">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.53" spread="6.15"/>
                    <measurement group_id="O2" value="36.53" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.99">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.70" spread="7.62"/>
                    <measurement group_id="O2" value="35.89" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.25" spread="21.32"/>
                    <measurement group_id="O2" value="30.97" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.99" spread="10.08"/>
                    <measurement group_id="O2" value="36.72" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.97" spread="13.22"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.47" spread="8.72"/>
                    <measurement group_id="O2" value="35.13" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>not adjusted for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction</title>
        <description>Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <description>Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal.</description>
          <population>intent to treat</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.62" spread="5.25"/>
                    <measurement group_id="O2" value="62.09" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.90">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.80" spread="6.15"/>
                    <measurement group_id="O2" value="61.29" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.90">n=1</measurement>
                    <measurement group_id="O2" value="54.81">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.70" spread="6.87"/>
                    <measurement group_id="O2" value="62.77" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.70" spread="16.03"/>
                    <measurement group_id="O2" value="68.47" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.95" spread="8.23"/>
                    <measurement group_id="O2" value="62.05" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.79" spread="11.20"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.95" spread="8.27"/>
                    <measurement group_id="O2" value="63.02" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>not adjusted for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic Longitudinal Strain</title>
        <description>Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Longitudinal Strain</title>
          <description>Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart.</description>
          <population>intent to treat</population>
          <units>percent/%Systolic interval</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.94" spread="27.44"/>
                    <measurement group_id="O2" value="82.55" spread="29.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.07">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.90" spread="34.56"/>
                    <measurement group_id="O2" value="78.68" spread="22.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.85" spread="26.07"/>
                    <measurement group_id="O2" value="80.04" spread="20.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.95" spread="20.87"/>
                    <measurement group_id="O2" value="88.34" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.11" spread="34.96"/>
                    <measurement group_id="O2" value="79.29" spread="22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.53" spread="26.81"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.94" spread="24.24"/>
                    <measurement group_id="O2" value="85.18" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>not adjusted for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Early Filling Rate: Rate of Change Over Time</title>
        <description>Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle.</description>
        <time_frame>5 visits per Participant over 2 years (about every 6 months)</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Pill that looks like Toprol XL but does not have the active ingredients</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Generic name metoprolol succinate</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Early Filling Rate: Rate of Change Over Time</title>
          <description>Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle.</description>
          <population>intent to treat</population>
          <units>EDV/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="0.61"/>
                    <measurement group_id="O2" value="2.12" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.53"/>
                    <measurement group_id="O2" value="2.08" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56">n=1</measurement>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.52"/>
                    <measurement group_id="O2" value="2.24" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.56"/>
                    <measurement group_id="O2" value="2.28" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.63"/>
                    <measurement group_id="O2" value="2.26" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=5,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.99"/>
                    <measurement group_id="O2" value="NA">no observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.60"/>
                    <measurement group_id="O2" value="2.25" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The differences in the rate of progression of the outcome measures were the focus of the comparisons over time between the treatment groups. A significant interaction effect between time and treatment group in the mixed model is the measure of treatment effect. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes and the number of Participants for each interval is indicated as (n=x,y)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>not adjusted for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>visit is every 6 months</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Toprol-XL</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral Valve Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mitral valve repair</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss and tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Continued right calf pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostrate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion and thoracentesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death due to bloodclot two weeks after liposuction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperlipidemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nodule rt of thyroid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>colon polyp removed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>left foot pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>left upper arm broken</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>tendonitis rt shoulder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Louis J. Dell'Italia, M.D.</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-0850</phone>
      <email>loudell@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

